Featured Article
The artificial intelligence system nearly doubled the ability of clinicians to identify high-risk esophageal lesions (HrELs)--consisting of esophageal cancer or precancerous lesions--compared with unassisted endoscopy.
Precision Oncology Today
Magazine
Beginning a New Era of Precision Alzheimer’s Therapeutics
Alzheimer’s is a disease associated with aging and impacts almost seven million people in the U.S. over the age of 65, with women and Black or Hispanic populations disproportionately affected by the condition. Finding an effective treatment for Alzheimer’s disease has proved to be a long and difficult quest.
5 Startups With Proteomics Potential Attracting Investor Cash
Investor appetite is growing for startups that can make proteomics faster, cheaper, and more informative for use in precision medicine. Here are five proteomics...
Trending on Inside Precision Medicine
Immunotherapy Significantly Extends Survival Post-Kidney Cancer Surgery
In a clinical trial, researchers at the Dana-Farber Cancer Institute in Boston, MA have demonstrated that administering the immunotherapy drug pembrolizumab after surgery can significantly improve overall survival rates for patients with a high risk of recurring kidney cancer.
Deep Learning Could Improve Esophageal Cancer Screening
The artificial intelligence system nearly doubled the ability of clinicians to identify high-risk esophageal lesions (HrELs)--consisting of esophageal cancer or precancerous lesions--compared with unassisted endoscopy.
Breakthrough Imaging Approved for Residual Breast Cancer Detection after Lumpectomy
The FDA has approved the LUMISIGHT (pegulicianine) optical imaging agent and the Lumicell Direct Visualization System to detect residual breast cancer after lumpectomy.
